Clinical trial

Rebif® Rebidose® Versus Rebiject II® Ease-of-Use

NCT02019550

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2014-03-01

PhasePHASE4

Study timeline

Study start (unknown)2014-03-01Date precision: month

Registry last updated2017-03-07

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Multiple Sclerosis, Relapsing-Remittingunresolved

Interventions

Rebif RebidoseDEVICE

Rebiject IIDEVICE

Sponsors & collaborators

EMD Seronolead sponsor

Mapped research locations

AtlantaGeorgia, United States1 MiamiFlorida, United States1 IndianapolisIndiana, United States1 Oklahoma CityOklahoma, United States1 Winston-SalemNorth Carolina, United States1 DaytonOhio, United States1 KnoxvilleTennessee, United States1 SpartanburgSouth Carolina, United States1 Newport BeachCalifornia, United States1 Fort CollinsColorado, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT02019550 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.